Esperion Therapeutics Inc (ESPR) — Cash Flow Quality Index
Latest as of March 2024:
0.88x
Esperion Therapeutics Inc (ESPR) has a Cash Flow Quality Index of 0.88x as of March 2024. Operating cash flow of $53.83 Million is below net income of $61.02 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore ESPR operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
0.88x
Operating CF / Net Income
Operating Cash Flow
$53.83 Million
USD
Net Income
$61.02 Million
USD
Data as of
Mar 2024
Most recent filing
Annual Cash Flow Quality Index for Esperion Therapeutics Inc (None–None)
Year-by-year earnings quality comparison for Esperion Therapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.